SAN2668

SAN2668 is a small molecule therapeutic candidate being developed by Saniona, in collaboration with Boehringer Ingelheim, for the treatment of epilepsy and rare pediatric epilepsy syndromes, including developmental and epileptic encephalopathies (DEEs). The drug is currently in Phase 2a clinical development for general epilepsy and Phase 1 for rare pediatric syndromes. While the specific molecular target and mechanism of action have not been publicly disclosed in available pipeline assets, the compound originates from Saniona's research platform, which specializes in ion channel modulation for central nervous system disorders.